

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-20. (Canceled).

21. (Currently Amended) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO:809, wherein said polypeptide is overexpressed in lung cancer tissue.

22. (Canceled).

23. (Currently Amended) The polypeptide of claim 21-~~or~~22, wherein the polypeptide binds an antibody specific for a polypeptide with an amino acid sequence of SEQ ID NO:809.

24. (Currently Amended) An isolated polypeptide comprising an immunogenic portion of the amino acid sequence of SEQ ID NO:809, wherein said immunogenic portion comprises at least ten consecutive amino acid residues of the sequence of SEQ ID NO:809.

25. (Previously Presented) The isolated polypeptide of claim 24, wherein the immunogenic portion consists of contiguous amino acid residues of SEQ ID NO:809 selected from the group consisting of: 16-35, 21-35, 21-40, 26-45, 31-50, 71-90, 86-105, 91-110, 96-115, 101-120, 106-125, 111-130, 116-135, 131-150, and 141-160.